PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB
Krisztina Kovács(ECD for the Masses (United States)), Balázs Sümegi(University of Szeged)
Cited by 39
Related Papers
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
|British Journal of Pharmacology|2017|210
Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseases
|Biochemical Pharmacology|2018|97
A population‐based epidemiological study of neuromyelitis optica spectrum disorder in Hungary
|European Journal of Neurology|2019|41
PARP Inhibition Attenuates Acute Kidney Allograft Rejection by Suppressing Cell Death Pathways and Activating PI-3K-Akt Cascade
|PLoS ONE|2013|17
The Hungarian population-based prevalence and incidence study of neuromyelitis optica spectrum disorder.
|University of Southern Denmark Research Portal (University of Southern Denmark)|2018|16